# Debbie Dumont

> Debbie Dumont is a Series A investor at Bioqube Ventures backing Biotechnology and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures)
- Location: San Francisco, United States
- Total investments: 4
- Last investment: Jan 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/debbiedumont

Debbie Dumont is a Series A investor at Bioqube Ventures in San Francisco focused on Biotechnology and Health Care. Debbie Dumont

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Life Science | 1 | 25% |
| Therapeutics | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 50% |
| Norway | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $23.3M | Series B | Jan 26, 2026 |  |
| Actithera | Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M | Series A | Jul 09, 2025 |  |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $4M | Series A | Jan 12, 2021 |  |
| Enhanc3D Genomics | Enhanc3D Genomics is a spinout company from Babraham Institute. |  | Seed | Jan 01, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 2 deals together
- [Oberland Capital](https://shizune.co/investors/profile/oberland-capital) — VC Fund, 2 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 1 deal together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together
- [Innovestor](https://shizune.co/investors/profile/innovestor) — VC Fund, 1 deal together

## About Bioqube Ventures

VC Fund · Hasselt, Belgium

Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.

5 contacts available at Bioqube Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Debbie Dumont | Co-founder and Managing Partner | https://shizune.co/investors/profile/debbie-dumont |
| Debora Dumont | Co-Founder & Managing Partner | https://shizune.co/investors/profile/debora-dumont |
| Dirk Reyn | Managing Partner | https://shizune.co/investors/profile/dirk-reyn |
| Nico Vandervelpen | Co-founder and Managing Partner | https://shizune.co/investors/profile/nico-vandervelpen |
| Tom Heyman | Executive Partner | https://shizune.co/investors/profile/tom-heyman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Debbie Dumont invest in?

Debbie Dumont invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Debbie Dumont last invest?

The most recent investment recorded for Debbie Dumont closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co